AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $10.2B covered $5.7B of dividends and buybacks. Cash fell by $163.0M. Lines the picture does not name came to −$5.0B. What is a cash flow statement?
- Free cash flow
- $10.2B 77.3% of operating cash flow
- Returned to shareholders
- $5.7B 55.7% of free cash flow
- Debt, net
- $564.0M borrowed
- Change in cash
- −$163.0M over the period
| Operating cash flow | 13.2 |
|---|---|
| Capital expenditures | −3.0 |
| Free cash flow | 10.2 |
| Into investments, net | −0.2 |
| Dividends | −5.0 |
| Buybacks, net | −0.7 |
| Debt raised, net | +0.6 |
| Other | −5.0 |
| Change in cash | −0.2 |
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $14.6B | $14.2B | $13.7B | $13.2B |
| Capex | −$2.8B | −$2.9B | −$3.0B | −$3.0B |
| Free cash flow | $11.8B | $11.3B | $10.7B | $10.2B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
12,402.00 | 12,914.00 | 12,586.00 | 13,300.00 |
Depreciation & Amortization |
5,733.00 | 5,815.00 | 6,355.00 | 6,411.00 | |
Non Cash Items (Other) |
1,738.00 | 1,546.00 | 1,233.00 | 1,132.00 | |
Accounts Receivable Change |
(6,126.00) | — | — | — | |
Change in inventories |
2,386.00 | — | — | — | |
Accounts Payable Change |
5,767.00 | — | — | — | |
Change in other assets and liabilities |
— | (936.00) | (948.00) | (895.00) | |
Other operating activities |
(4,161.00) | (4,343.00) | (4,670.00) | (4,680.00) | |
Operating Cash Flow |
14,575.00 | 14,221.00 | 13,700.00 | 13,232.00 | |
Capital expenditures |
(2,797.00) | (2,908.00) | (3,017.00) | (3,006.00) | |
Change in intangibles (net) |
(2,959.00) | (3,374.00) | (4,418.00) | (3,893.00) | |
Net Aquisitions |
(1,324.00) | — | — | — | |
Short Term Investments Change (Net) |
131.00 | 45.00 | (29.00) | (187.00) | |
Long-Term Investments Change (Net) |
(234.00) | (271.00) | (80.00) | (40.00) | |
Other investing activities |
286.00 | 391.00 | 623.00 | 254.00 | |
Investing cash flow |
(6,808.00) | (7,347.00) | (8,151.00) | (8,035.00) | |
Repayment/Issuance of Debt (Net) |
(2,022.00) | 1,192.00 | (1,888.00) | 564.00 | |
Equity Repurchase (Common, Net) |
(481.00) | (605.00) | (646.00) | (733.00) | |
Dividends Paid (Total) |
(4,971.00) | (4,911.00) | (4,902.00) | (4,958.00) | |
Other financial activities |
(70.00) | (246.00) | (244.00) | (221.00) | |
Financing cash flow |
(7,544.00) | (4,570.00) | (7,680.00) | (5,348.00) | |
Exchange Rate Adjustment |
46.00 | 3.00 | (17.00) | (12.00) | |
Change in Cash |
269.00 | 2,307.00 | (2,148.00) | (163.00) | |
Beginning Cash |
5,429.00 | 5,698.00 | 5,698.00 | 5,698.00 | |
Ending Cash |
5,698.00 | 8,005.00 | 3,550.00 | 5,535.00 | |
Dividends Paid (Common) |
(4,971.00) | (4,911.00) | (4,902.00) | (4,958.00) | |
Assets Liabilities Change (Total) |
(1,137.00) | (1,711.00) | (1,804.00) | (2,931.00) | |
Investments Change (Net) |
(108.00) | (226.00) | (109.00) | (227.00) | |
Issuance/Purchase of Shares |
(481.00) | (605.00) | (646.00) | (733.00) |